Screener
TransMedics Group, Inc. TMDX Service Unrelated To OCS Transplant — Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by TransMedics Group, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The source filing: TransMedics Group, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-206453
FAQ
- What is TransMedics Group, Inc.'s service unrelated to OCS transplant — revenue?
- TransMedics Group, Inc. (TMDX) reported service unrelated to OCS transplant — revenue of $1.3M in Q1 2026.
- How has TransMedics Group, Inc.'s service unrelated to OCS transplant — revenue changed year-over-year?
- TransMedics Group, Inc.'s service unrelated to OCS transplant — revenue increased by 44.4% year-over-year, from $900K to $1.3M.
- What is the long-term trend for TransMedics Group, Inc.'s service unrelated to OCS transplant — revenue?
- Over 2 years (2023 to 2025), TransMedics Group, Inc.'s service unrelated to OCS transplant — revenue has grown at a -8.5% compound annual growth rate (CAGR), from $4.9M to $4.1M.
- What does service unrelated to OCS transplant — revenue mean?
- This metric represents the total revenue generated from secondary service offerings that are not directly integrated with the company's core Organ Care System (OCS) transplant technology platform. It captures income streams from legacy or ancillary business activities that fall outside the primary focus of organ perfusion and optimization services. Tracking this revenue helps investors evaluate the company's reliance on non-core business segments as it transitions toward a specialized medical technology model.
Ask your AI about TransMedics Group, Inc.'s service unrelated to ocs transplant — revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude